Purchase Order 75N95023P00342
Award Date
6/9/23
Potential Completion Date
9/30/25
Potential Value
$205K
Funding Federal Agency
National Center for Advancing Translational Sciences
Contracting Federal Agency
National Institute on Drug Abuse
Awardee
Charles River Laboratories, Inc.
Ultimate Awardee
Not listed
NAICS Category
541380 - Testing Laboratories and Services
PSC Category
Q301 - Reference Laboratory Testing
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Wilmington, MA 01887, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $55,260 federal contract awarded by the National Center for Advancing Translational Sciences (NCATS), a center within the National Institutes of Health (NIH), to Charles River Laboratories, Inc. The contract is for the testing of 10 small molecule compounds in rat pharmacokinetic experiments. The original solicitation was a Small Business Sources Sought notice seeking qualified small businesses capable of performing this type of specialized preclinical research. The contract does not...
The National Institutes of Health's National Center for Advancing Translational Sciences awarded a $11,000 purchase order to Charles River Laboratories, Inc. for pharmacology services in CD-1 mice. Charles River will perform the requested preclinical research services at its facility in Wilmington, Massachusetts to support NIH's efforts to translate basic science into new and better patient treatments, diagnostics and prevention strategies. No subcontractors or set aside designations were...
The National Center for Advancing Translational Sciences (NCATS), a civilian agency within the Department of Health and Human Services, has awarded a $96,829.63 firm-fixed-price purchase order to Insphero Inc., a foreign-owned, for-profit manufacturer of 3D cell culture technologies. The contract is for a Transcriptomics study - RNA-seq in Liver Spheroids Phase One, with the purpose of evaluating the safety and liver toxicity of candidate antisense oligonucleotides using a 3D liver microtissue...
This federal contract was awarded by the National Institutes of Health (NIH) Clinical Center to Charles River Laboratories, Inc. (also known as Charles River Laboratories Ashland LLC) for toxicity testing on a new Positron Emission Tomography (PET) ligand called Fluoine-18-Fluorocellobiose. The $216,035.00 firm fixed-price purchase order has an ultimate completion date of April 24, 2026 and does not have a set-aside designation. The contract requires Charles River to perform a single-dose,...
This is a $90,414 firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the Department of Health and Human Services, to Insphero Inc., a foreign-owned, for-profit manufacturer of 3D cell culture technologies and in vitro models. The contract is for a Liver Assay in Liver Spheroids to evaluate the toxicity of short interfering RNA (siRNA) and antisense oligonucleotides (ASOs), which are increasingly being used as...
The National Center for Advancing Translational Sciences (NCATS), part of the U.S. Department of Health and Human Services, awarded a $83,000.00 firm fixed-price purchase order to Poochon Scientific LLC, a minority-owned small business, for Protein Identification of Mixture Samples by LC/MS/MS and Proteomic Profiling of Antisense Oligonucleotide (ASO) Treated Brain Organoids. This non-competitive, commercial item acquisition is being conducted under simplified acquisition procedures by the...
The National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services (HHS), has awarded a $124,200.00 firm fixed-price purchase order contract to Pharmaron, Inc., a minority-owned business based in China, to evaluate the pharmacokinetics of compounds from dystonia in mice, dogs, and rats. This sole-source contract, awarded under simplified acquisition procedures, will require Pharmaron to provide consistency and...
This firm fixed-price purchase order was awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health within the Department of Health and Human Services, to Pharmaron, Inc. for $64,090. The contract is for Pharmaron to conduct a 14-day dose range-finding toxicity study in male and female rats to determine the maximally tolerated dose of an investigational molecule under development by NCATS. Specifically, Pharmaron will test the...
The National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), awarded a $23,940.00 firm-fixed-price purchase order to Life Technologies Corporation, a division of Thermo Fisher Scientific, for a View RNA in situ hybridization (ISH) cell assay kit. This acquisition supports NCATS' Cooperative Research and Development Agreement (CRADA) for Alagille syndrome (ALGS) research, specifically to screen compound libraries for activators of the...
This is a $35,600 firm fixed price purchase order contract awarded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Pharmaron, Inc., a minority-owned for-profit organization, to conduct a mouse study evaluating NNMT inhibitors in high grade serous ovarian cancer. The work, which has a 12-month period of performance, involves formulating compounds, developing a mouse model, conducting efficacy studies, and analyzing samples. No set-aside...